• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Panbela Therapeutics Inc.

    1/10/25 4:50:26 PM ET
    $PBLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PBLA alert in real time by email
    S-8 1 pbla20250109_s8.htm FORM S-8 pbla20250109_s8.htm

     

    As filed with the Securities and Exchange Commission on January 10, 2025.

    Registration No. 333‑                   

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D. C. 20549

     

    Form S-8

     

    REGISTRATION STATEMENT UNDER THE

    SECURITIES ACT OF 1933

     

     

    PANBELA THERAPEUTICS, INC. 

     
     

    (Exact Name of Registrant as Specified in its Charter)

     

     

    Delaware

     

    88-2805017

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer
    Identification No.)

         

    712 Vista Blvd #305
    Waconia, MN

     

    55387

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    2016 Omnibus Incentive Plan

    (Full Title of the Plan)

     

     

    Susan Horvath

    Chief Financial Officer

    Panbela Therapeutics, Inc.

    712 Vista Blvd #305

    Waconia, MN 55387

    (Name and Address of Agent for Service)

     

     

    Telephone number, including area code, of agent for service: (952) 479-1196

     

     


    Copies to:

    W. Morgan Burns

    Joshua L. Colburn

    Faegre Drinker Biddle & Reath LLP

    2200 Wells Fargo Center

    90 South Seventh Street

    Minneapolis, Minnesota 55402‑3901

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non‑accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large Accelerated Filer ☐

    Accelerated Filer ☐

    Non‑accelerated Filer ☑

    Smaller Reporting Company ☑

     

    Emerging Growth Company ☐

                                                                       

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

    PANBELA THERAPEUTICS, INC.

     

    STATEMENT PURSUANT TO GENERAL INSTRUCTION E
    TO FORM S-8 “REGISTRATION OF ADDITIONAL SECURITIES”

     

    The stockholders of Panbela Therapeutics, Inc., (the “Company”) initially approved the Company’s 2016 Omnibus Incentive Plan on May 17, 2016. On May 19, 2020, the stockholders of the Company approved an amendment and restatement of the Company’s 2016 Omnibus Incentive Plan (as amended and restated, the “2016 Plan”). The 2016 Plan provides, among other things, that the number of shares of the Company’s common stock available for issuance under the plan will increase on January 1 of each year beginning in 2021 and ending on January 1, 2025 in an amount equal to the lesser of (i) the number of shares necessary to increase the total option pool to 20% of the total number of fully diluted shares (as defined in the 2016 Plan) as of December 31 of the immediately preceding calendar year and (ii) such lesser number of shares as may be determined by the Company’s Board of Directors or its Compensation Committee prior to January 1st of any calendar year.

     

    Pursuant to General Instruction E to Form S-8, the contents of the Initial Registration Statement (filed on Form S-8 with the Securities and Exchange Commission on June 15, 2020, file no. 333-239186), together with all exhibits filed therewith or incorporated therein by reference, are incorporated herein by reference.

     

    The Company has filed this registration statement on Form S-8 to register the 9,144,117 additional shares of Common Stock, not previously registered under the 2016 Plan, that became available for issuance under the 2016 Plan effective as of January 1, 2025.

     

    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 8.    Exhibits.

     

    Exhibit

    Number

     

    Description of Exhibit

    4.1

     

    Certificate of Amendment of Amended and Restated Certificate of Incorporation of Panbela Therapeutics, Inc. (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed on January 19, 2024)

    4.2

     

    Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 to current report on Form 8-K filed April 18, 2023).

    5.1+

     

    Opinion of Faegre Drinker Biddle & Reath LLP

    23.1+

     

    Consent of Independent Registered Public Accounting Firm (Cherry Bekaert LLP)

    23.2+

     

    Consent of Faegre Drinker Biddle & Reath LLP (included in Exhibit 5.1)

    24

     

    Powers of Attorney (included with signatures)

    99.1

     

    2016 Omnibus Incentive Plan (incorporated by reference to Exhibit 99.1 to current report on Form 8-K filed May 26, 2020)

    107+

     

    Filing Fee Table

     

     


    + Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S‑8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota, on January 10, 2025.

     

     

    PANBELA THERAPEUTICS, INC.

         
     

    By:

    /s/ Jennifer K. Simpson

       

    Name: Jennifer K. Simpson

       

    Title: President and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below hereby constitutes and appoints Jennifer K. Simpson and Susan Horvath, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, with full powers of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign the Registration Statement filed herewith and any and all amendments to said Registration Statement (including post-effective amendments), and file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, with full power of each to act alone, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons on behalf of the Registrant and in the capacities indicated on January 10, 2025:

     

    Signature

     

    Title

         

    /s/ Jennifer K. Simpson

     

    President and Chief Executive Officer

    Jennifer K. Simpson

     

    (principal executive officer)

         

    /s/ Susan Horvath

     

    Vice President of Finance, Chief Financial Officer, Treasurer and Secretary

    Susan Horvath

     

    (principal financial and accounting officer)

         

    /s/ Michael T. Cullen

     

    Executive Chairman and Director

    Michael T. Cullen

       
         

    /s/ Daniel J. Donovan

     

    Director

    Daniel J. Donovan

       
         

    /s/ Arthur J. Fratamico

     

    Director

    Arthur J. Fratamico

       
         

    /s/ Jeffrey E. Jacob

     

    Director

    Jeffrey E. Jacob

       
         

    /s/ Jeffrey S. Mathiesen

     

    Director

    Jeffrey S. Mathiesen

       
         

    /s/ D. Robert Schemel

     

    Director

    D. Robert Schemel

       

     

     
    Get the next $PBLA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PBLA

    DatePrice TargetRatingAnalyst
    6/28/2021$10.00Buy
    Roth Capital
    More analyst ratings

    $PBLA
    Financials

    Live finance-specific insights

    See more
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

      MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) --  Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50956 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50956Webcast Replay: https://www.webc

      7/30/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

      MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/50531 Conference Call Replay Information Toll Free: 877-481-4010International: 919-882-2331Replay Passcode: 50531Webcast Replay: https://www.webcas

      5/1/24 4:15:00 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Panbela Therapeutics with a new price target

      Roth Capital initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $10.00

      6/28/21 6:58:09 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/16/21 8:15:44 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Panbela Therapeutics with a new price target

      Maxim Group initiated coverage of Panbela Therapeutics with a rating of Buy and set a new price target of $8.00

      3/10/21 9:33:23 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    SEC Filings

    See more
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/18/25 4:32:54 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      2/4/25 4:02:40 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela Therapeutics Inc. filed SEC Form 8-K: Events That Accelerate or Increase a Direct Financial Obligation, Changes in Control of Registrant

      8-K - Panbela Therapeutics, Inc. (0001029125) (Filer)

      1/22/25 4:02:43 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Panbela Provides Business Update and Reports Q3 2024 Financial Results

      MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic investor, Nant Capital.First patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). Jennifer K. Simpson,

      11/14/24 4:10:36 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

      MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), ("Panbela"), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494Webcast Link: https://www.webcaster4.com/Webcast/Page/2556/51548 Conference Call Replay InformationToll Free: 877-481-4010International: 919-882-2331Replay Passcode: 51548Webcast Replay: https://www.

      10/31/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

      MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combination with the immune checkpoint inhibitor Keytruda, while evaluating efficacy and then moving into a Phase II efficacy trial. Data from the Phase I trial is expected by mid-2025, with a look to start

      9/24/24 8:00:00 AM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Nant Capital, Llc

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      11/19/24 6:40:08 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Nant Capital, Llc

      3 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/29/24 7:38:18 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by V.P. of Finance & CFO Horvath Susan

      4 - Panbela Therapeutics, Inc. (0001029125) (Issuer)

      10/3/24 4:26:59 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PBLA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Panbela Therapeutics Inc.

      SC 13D - Panbela Therapeutics, Inc. (0001029125) (Subject)

      10/29/24 7:40:55 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/13/24 8:10:27 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Panbela Therapeutics Inc. (Amendment)

      SC 13G/A - Panbela Therapeutics, Inc. (0001029125) (Subject)

      2/14/23 2:45:11 PM ET
      $PBLA
      Biotechnology: Pharmaceutical Preparations
      Health Care